Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1983 Apr;36(4):449–453. doi: 10.1136/jcp.36.4.449

Impairment of neutrophil chemotaxis by serum from patients with chronic lymphoproliferative disease.

U Jayaswal, S Roper, S Roath
PMCID: PMC498243  PMID: 6833512

Abstract

The sera of 74 individuals with chronic lymphoproliferative disease were screened for the presence of inhibitory activity against neutrophil chemotaxis. This was present in more than half the patients with IgA myeloma and Hodgkin's disease but was less common in chronic lymphocytic leukaemia, lymphocytic lymphoma and non-IgA paraproteinaemia. Heating the sera prior to testing frequently enhanced inhibitory activity particularly in myeloma and lymphoma.

Full text

PDF
449

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Addison I. E., Babbage J. W. A raft technique for chemotaxis: a versatile method suitable for clinical studies. J Immunol Methods. 1976;10(4):385–388. doi: 10.1016/0022-1759(76)90033-8. [DOI] [PubMed] [Google Scholar]
  2. BOYDEN S. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med. 1962 Mar 1;115:453–466. doi: 10.1084/jem.115.3.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Becker E. L., Showell H. J. The ability of chemotactic factors to induce lysosomal enzyme release. II. The mechanism of release. J Immunol. 1974 Jun;112(6):2055–2062. [PubMed] [Google Scholar]
  4. Broder S., Humphrey R., Durm M., Blackman M., Meade B., Goldman C., Strober W., Waldmann T. Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. N Engl J Med. 1975 Oct 30;293(18):887–892. doi: 10.1056/NEJM197510302931801. [DOI] [PubMed] [Google Scholar]
  5. Casazza A. R., Duvall C. P., Carbone P. P. Infection in lymphoma. Histology, treatment, and duration in relation to incidence and survival. JAMA. 1966 Aug 29;197(9):710–716. doi: 10.1001/jama.197.9.710. [DOI] [PubMed] [Google Scholar]
  6. Casazza A. R., Duvall C. P., Carbone P. P. Summary of infectious complications occurring in patients with Hodgkin's disease. Cancer Res. 1966 Jun;26(6):1290–1296. [PubMed] [Google Scholar]
  7. Cawley J. C., Smith J., Goldstone A. H., Emmines J., Hamblin J., Hough L. IgA and IgM cytoplastic inclusions in a series of cases of chronic lymphocytic leukaemia. Clin Exp Immunol. 1976 Jan;23(1):78–82. [PMC free article] [PubMed] [Google Scholar]
  8. Dale D. C., Fauci A. S., Wolff S. M. Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections. N Engl J Med. 1974 Nov 28;291(22):1154–1158. doi: 10.1056/NEJM197411282912203. [DOI] [PubMed] [Google Scholar]
  9. Epps D. E., Williams R. C., Jr Serum chemotactic inhibitory activity: heat activation of chemotactic inhibition. Infect Immun. 1976 Mar;13(3):741–749. doi: 10.1128/iai.13.3.741-749.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gallin J. I., Durocher J. R., Kaplan A. P. Interaction of leukocyte chemotactic factors with the cell surface. I. Chemotactic factor-induced changes in human granulocyte surface charge. J Clin Invest. 1975 May;55(5):967–974. doi: 10.1172/JCI108026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jayaswal U., Roath S., Hyde R. D., Chisholm D. M., Smith J. L. Blood lymphocytes surface markers and clinical findings in chronic lympoproliferative disorders. Br J Haematol. 1977 Oct;37(2):207–215. doi: 10.1111/j.1365-2141.1977.tb06836.x. [DOI] [PubMed] [Google Scholar]
  12. Jayaswal U., Roper S., Roath S. Granulocyte chemotaxis: multiple assay screening using a raft technique. J Clin Pathol. 1982 Feb;35(2):182–185. doi: 10.1136/jcp.35.2.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. MILLER D. G., BUDINGER J. M., KARNOFSKY D. A. A clinical and pathological study of resistance to infection in chronic lymphatic leukemia. Cancer. 1962 Mar-Apr;15:307–329. doi: 10.1002/1097-0142(196203/04)15:2<307::aid-cncr2820150214>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  14. Maderazo D. G., Ward P. A., Woronick C. L., Quintiliani R. Partial characterization of a cell-directed inhibitor of leukotaxis in human serum. J Lab Clin Med. 1977 Jan;89(1):190–199. [PubMed] [Google Scholar]
  15. Maderazo E. G., Anton T. F., Ward P. A. Serum-associated inhibition of leukotaxis in humans with cancer. Clin Immunol Immunopathol. 1978 Feb;9(2):166–176. doi: 10.1016/0090-1229(78)90068-5. [DOI] [PubMed] [Google Scholar]
  16. Martin R. R., Warr G. A., Couch R. B., Yeager H., Knight V. Effects of tetracycline on leukotaxis. J Infect Dis. 1974 Feb;129(2):110–116. doi: 10.1093/infdis/129.2.110. [DOI] [PubMed] [Google Scholar]
  17. Penny R., Castaldi P. A., Whitsed H. M. Inflammation and haemostasis in paraproteinaemias. Br J Haematol. 1971 Jan;20(1):35–44. doi: 10.1111/j.1365-2141.1971.tb00784.x. [DOI] [PubMed] [Google Scholar]
  18. Ruutu T., Ruutu P., Vuopio P., Franssila K., Linder E. An inhibitor of chemotaxis and phagocytosis in reticulum cell sarcoma. Scand J Haematol. 1975 Aug;15(1):27–34. doi: 10.1111/j.1600-0609.1975.tb01052.x. [DOI] [PubMed] [Google Scholar]
  19. Stossel T. P., Mason R. J., Hartwig J., Vaughan M. Quantitative studies of phagocytosis by polymorphonuclear leukocytes: use of emulsions to measure the initial rate of phagocytosis. J Clin Invest. 1972 Mar;51(3):615–624. doi: 10.1172/JCI106851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Van Epps D. E., Williams R. C., Jr Suppression of leukocyte chemotaxis by human IgA myeloma components. J Exp Med. 1976 Nov 2;144(5):1227–1242. doi: 10.1084/jem.144.5.1227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ward P. A., Berenberg J. L. Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator. N Engl J Med. 1974 Jan 10;290(2):76–80. doi: 10.1056/NEJM197401102900203. [DOI] [PubMed] [Google Scholar]
  22. Zielinski C. C., Lanzer G., Ludwig H. P. Defects of leukocyte locomotion in multiple myeloma. J Clin Lab Immunol. 1982 Feb;7(2):111–114. [PubMed] [Google Scholar]
  23. Zigmond S. H., Hirsch J. G. Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor. J Exp Med. 1973 Feb 1;137(2):387–410. doi: 10.1084/jem.137.2.387. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES